中国组织工程研究

中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (2): 167-172.doi: 10.3969/j.issn.2095-4344.2016.02.003

• 骨组织构建 bone tissue construction • 上一篇    下一篇

组蛋白去甲基化酶JMJD2和雌激素受体相关受体α在绝经后骨质疏松症的表达

唐宏宇1，2，董路珏3，霍少川3，郭 承3，周 驰1，2，陈建发1，刘 勇3，王海彬1，2   

  1. 1广州中医药大学第一附属医院骨科中心，广东省广州市 510405；2广州中医药大学国家重点骨科实验室，广东省广州市 510405；3广州中医药大学，广东省广州市 510405
  • 收稿日期:2015-10-16 出版日期:2016-01-08 发布日期:2016-01-08
  • 通讯作者: 王海彬，博士，主任中医师，教授，博士生导师，广州中医药大学第一附属医院骨科中心，广东省广州市 510405
  • 作者简介:唐宏宇，男，1987年生，湖南省怀化市人，土家族，2015年广州中医药大学毕业，硕士，医师，主要从事骨质疏松、股骨头坏死以及骨关节炎等骨科疾病的研究。
  • 基金资助:
    国家自然科学基金(81373655)；广东省省级科技计划项目(2013B021800226)

Expression of jumonji domain-containing histone demethylase 2 and estrogen-related receptor alpha in postmenopausal osteoporosis

Tang Hong-yu1, 2, Dong Lu-jue3, Huo Shao-chuan3, Guo Cheng3, Zhou Chi1, 2, Chen Jian-fa1, Liu Yong3, Wang Hai-bin1, 2   

  1. 1Orthopedics Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; 2the National Key Research Laboratory of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; 3Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
  • Received:2015-10-16 Online:2016-01-08 Published:2016-01-08
  • Contact: Wang Hai-bin, M.D., Chief physician, Professor, Doctoral supervisor, Orthopedics Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; the National Key Research Laboratory of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
  • About author:Tang Hong-yu, Master, Physician, Orthopedics Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; the National Key Research Laboratory of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
  • Supported by:

    the National Natural Science Foundation of China, No. 81373655; Guangdong Provincial Science and Technology Plan Projects, No. 2013B021800226

PDF

742

摘要：

文章快速阅读：

文题释义：

雌激素相关受体：雌激素相关受体属于核受体超家族。是第一个发现的孤儿核受体, 包括雌激素相关受体α, 雌激素相关受体β和雌激素相关受体γ3种类型。雌激素相关受体的生物学功能主要体现在以不同的方式参与雌激素信号途径, 雌激素相关受体与雌激素受体在骨骼组织和乳腺组织中拥有共同的靶基因。

 

背景：研究发现组蛋白去甲基化酶具有促进成骨细胞分化的作用；雌激素相关受体α可促进成骨细胞分化，增加骨形成。然而绝经后骨质疏松症组蛋白去甲基化酶表达以及与雌激素受体相关受体α的相关性未见报道。

目的：观察绝经后骨质疏松症患者组蛋白去甲基化酶2家族的变化及其对组蛋白甲基化(H3K9me3、H3K36me3)水平的影响，以及与雌激素受体相关受体α的相关性。
方法：选择年龄50-70岁因髋关节骨性关节炎行关节置换的绝经后患者，通过检测腰椎骨密度，收集10例绝经后骨质疏松症患者(实验组)和10例非骨质疏松症患者(对照组)，术中提取股骨头松质骨标本，免疫组织化学、蛋白质印迹法检测骨组织中组蛋白去甲基化酶(JMJD2A、JMJD2B)、组蛋白甲基化(H3K9me3、H3K36me3)以及雌激素受体相关受体α的表达。

结果与结论：绝经后妇女组蛋白去甲基化酶2A、组蛋白去甲基化酶2B、雌激素受体相关受体α表达为弱阳性到阳性不等，骨质疏松症患者组表达水平低于非骨质疏松症患者组，组间差异有显著性意义(P < 0.05)；骨质疏松症患者组H3K9me3、H3K36me3表达水平高于非骨质疏松症患者组，组间差异有显著性意义(P < 0.05)。结果说明，绝经后骨质疏松症患者组蛋白呈高甲基化状态，组蛋白去甲基化酶2A、组蛋白去甲基化酶2B低表达，雌激素受体相关受体α水平与组蛋白去甲基化酶相一致；组蛋白去甲基化酶可能为骨质疏松的一种拮抗酶。 

ORCID: 0000-0003-4350-3049(唐宏宇)

关键词: 组织构建, 骨组织工程, 绝经后骨质疏松症, 表观遗传学, 组蛋白去甲基化酶JMJD2, 免疫组织化学, 蛋白质印迹, 雌激素受体相关受体α, 国家自然科学基金

Abstract:

 

BACKGROUND: Jumonji domain-containing histone demethylase (JMJD) can promote osteoblast differentiation, and estrogen-related receptor alpha (ERRα) can promote osteoblast differentiation and increase bone formation. However, little is reported on the association between postmenopausal osteoporosis and JMJD and ERRα.
OBJECTIVE: To study the changes in the JMJD2 family expression in patients with postmenopausal osteoporosis.

METHODS: Postmenopausal patients with osteoarthritis of the hip scheduled for total hip arthroplasty, aged 50-70 years, were enrolled, including 10 postmenopausal osteoporosis patients (experimental group) and 10 patients with no postmenopausal osteoporosis (control group). During the arthroplasty, the cancellous bone specimens from the femoral head were collected. Then, immunohistochemistry and western blot assay were used to detect expression of histone demethylase (JMJD2A, JMJD2B), histone methylation (H3K9me3, H3K36me3) and ERRα.

RESULTS AND CONCLUSION: In the experimental group, the expressions of JMJD2A, JMJD2B and ERRα were from weakly positive to positive; these expressions were significantly lower in the experimental group than the control group (P < 0.05). The expressions of H3K9me3 and H3K36me3 were significantly higher in the experimental group than the control group (P < 0.05). These findings indicate that the expression of JMJD2A and JMJD2B is consistent with the expression of ERRα in the patients with postmenopausal osteoporosis, and JMJD is likely to serve as an antagonistic enzyme of osteoporosis.